Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral's's Other Operating Expense for the
six
months ended in Sep. 2025 was ₹1,073 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was ₹1,073 Mil.
Sai Parenteral's's quarterly Other Operating Expense
stayed the same
from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then
increased
from Mar. 2025 (₹0 Mil) to Sep. 2025 (₹1,073 Mil).
Sai Parenteral's's annual Other Operating Expense
increased
from Mar. 2023 (₹190 Mil) to Mar. 2024 (₹284 Mil) and
increased
from Mar. 2024 (₹284 Mil) to Mar. 2025 (₹1,931 Mil).
Sai Parenteral's Other Operating Expense Related Terms
Sai Parenteral's Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1,073 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ₹1,073 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Other Operating Expense of ₹1,073 Mil as of Sep. 2025. Other operating expenses that a company records on its income statement. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Other Operating Expense too high?
Sai Parenteral's' current Other Operating Expense is ₹1,073 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Other Operating Expense compare to LLY and JNJ?
Sai Parenteral's' Other Operating Expense of ₹1,073 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Other Operating Expense is ₹1,073 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Other Operating Expense of ₹1,073 Mil. The current Other Operating Expense is ₹1,073 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Other Operating Expense is ₹1,073 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
